NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826.

Authors :: Herrera, A. F.
LeBlanc, M.
Castellino, S. M.
Li, H.
Rutherford, S. C.
Evens, A. M.
Davison, K.
Punnett, A.
Hodgson, D.
Parsons, S. K.
Ahmed, S.
Casulo, C.
Bartlett, N. L.
Tuscano, J. M.
Mei, M. G.
Hess, B. T.
Jacobs, R.
Saeed, H.
Torka, P.
Hu, B.
Source :: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p33-35, 3p
Publication Year :: 2023
Abstract: Rates (any gr) of febrile neutropenia (5.6% N vs. 6.4% BV), pneumonitis (2.0% N vs. 3.2% BV), ALT elevation (30.7% N vs. 39.8% BV), and colitis (1% N vs. 1.3% BV) were similar. B Background: b The addition of BV to initial chemotherapy improves outcomes in adult and pediatric patients (pts) with AS HL. NIVOLUMAB(N)-AVD IMPROVES PROGRESSION-FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)-AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826. [Extracted from the article]

Full Text Access

Tools